Highly experienced biotech executive, with over a quarter of a century of CNS drug discovery experience Beher takes over the role of Chief Executive Officer…
Read More
Appointment underscores FundaMental’s ambition to develop medicines for neurodegenerative diseases based on a breakthrough molecular mechanism Heidelberg, GERMANY, 20 March 2024 - FundaMental Pharma GmbH,…
Read More
Heidelberg, Germany – 17 November 2022 – FundaMental Pharma GmbH (“FundaMental”), a preclinical neuroscience company spun out of Heidelberg University, today announces that it has launched…
Read More
High-Tech Gründerfonds (HTGF) provides seed funding for the neuro start-up FundaMental Pharma GmbH (FMP), a spin-off of the Interdisciplinary Center for Neuroscience (IZN) at Heidelberg…
Read More
Jones S A New Villain in Neuronal Death – A newly discovered partnership for glutamate triggers brain toxicity Science 370, eaay3302 , doi: 10.1126/science.abe2791. Abstract…
Read More
Yan J, Bengtson P, Buchthal B, Hagenston A, Bading H. Coupling of NMDA receptors and TRPM4 guides discovery of unconventional neuroprotectants. Science 370, eaay3302 ,…
Read More
Heidelberg neurobiologists decode central mechanism of degenerative processes in the brains of mouse models and develop new principle for therapeutic agents Neurobiologists at Heidelberg University…
Read More
